Phaseline

Targets › CCL21

CCL21 (C-C motif chemokine 21): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4. Binds to chemokine receptor CCR7. (UniProt, O00585)

Open in Phaseline: the race on CCL21, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Jonsson Comprehensive Cancer CenterAutologous Dendritic Cell-Adenovirus CCL21 Vaccine
CCL21-gene modified dendritic cell vaccine delivered via adenovirus vector
CCL21Phase 1Lung Non-Small Cell CarcinomaJan 2027

Conditions

Lung Non-Small Cell Carcinoma (1)

Modalities

mixed (1)

Companies

Jonsson Comprehensive Cancer Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.